onyx pharma - 500 Beiträge pro Seite

[frank55]

Xenogen Corporation Grants SUGEN, Inc. Commercial License to Patented Real-Time `In Vivo` Imaging Technology


ALAMEDA, Calif., May 31, 2001 /PRNewswire via COMTEX/ -- Xenogen Corporation
today announced that it has entered into a commercial licensing agreement with
SUGEN, Inc. for its real-time `in vivo` imaging technology. This agreement
grants SUGEN access to Xenogen`s proprietary suite of technologies for use in
pre-clinical drug development studies.

This multi-year agreement, which includes annual fees and milestone payments,
was reached without the customary trial period, which SUGEN elected to forgo
given their high level of confidence in Xenogen`s technology. This commercial
license follows recently entered into agreements with leading pharmaceutical and
biotechnology companies including a commercial license with Novartis
Pharmaceutical Corporation and the evaluation licenses with AstraZeneca, Cell
Genesys, Chiron, Cubist Pharmaceuticals, DuPont Pharmaceuticals, Onyx
Pharmaceuticals and Organon.

Xenogen`s technology represents a novel approach to the biological assessment of
new chemical entities (NCEs) -- compounds that serve as the basis for new drugs.
Advantages offered by Xenogen`s technology include providing higher quality data
at earlier time points, potentially resulting in a better selection of drug
development candidates and significant time and cost savings.

"Xenogen is pleased to enter into this commercial agreement that will place our
technology within SUGEN`s high quality drug discovery and development groups,"
said Pamela Reilly Contag, Ph.D., president and co-CEO of Xenogen Corporation.
"The SUGEN commercial license represents another milestone for Xenogen in the
commercialization of our technology and allows for access to SUGEN`s proprietary
compounds to assist Xenogen in developing new bioluminescent applications."

About the Technology

Xenogen`s patented real-time in vivo imaging technology enables the detection of
fluorescent or bioluminescent cells (e.g., tumor cells and bacteria) inside
intact living animals, allowing non-invasive visualization and tracking of the
cells to monitor the effects of treatment with NCEs in vivo in real time. The
technology also provides researchers with a way to localize and follow the
expression of selected genes in vivo in Xenogen`s LPTATM light-producing
transgenic animals.

Real-time in vivo imaging offers pharmaceutical companies like SUGEN a number of
benefits to help increase the productivity of their drug development pipelines.
Compared to traditional methods, Xenogen believes that its technology provides
improved, more predictive data and thus a better selection process for drug
development candidates. In addition, Xenogen believes that its technology allows
researchers to conduct assessments more rapidly and efficiently with the
resulting reduction in labor and other material costs leading to significant
overall cost savings.

About SUGEN, Inc.

SUGEN, Inc., a wholly-owned subsidiary of Pharmacia Corporation, is a leading
biopharmaceutical company, focusing on the discovery and development of small
molecule drugs that target signal transduction pathways. These cell-signaling
pathways regulate the way messages are transmitted from outside a cell into the
cell itself, where the messenger molecules trigger key cellular events,
including gene expression. SUGEN`s research focuses on specific cell-surface
receptors or intracellular signaling molecules known as tyrosine kinases (TKs),
serine-threonine kinases (STKs), and phosphatases (PTPases). Abnormal signaling
involving these cell receptors or intracellular signaling has been shown to
result in a variety of chronic and acute pathological diseases, including cancer
and diabetes, as well as dermatologic, ophthalmic, neurologic, and immune
disorders.

About Xenogen Corporation

Xenogen Corporation is a leader in the field of real-time in vivo imaging,
providing the pharmaceutical industry with proprietary technologies, products
and services to enable real-time in vivo monitoring to identify drug leads for
clinical development. In addition to pharmaceutical development, Xenogen
believes that its technology has broad applications in other fields, including
biomedical research and toxicology testing in the chemical industry.

[chartmike]

Hallo,
Jetzt rein in ONYX (ONXX)

Der Stochastik hat schon nach oben gedreht, MACD folgt in kürze!
Chartmike